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Abstract
Background: Dopamine transporter (DaT) imaging (DaTSCAN) is useful for the
differential diagnosis of parkinsonian syndromes. Visual evaluation of DaTSCAN
images represents the generally accepted diagnostic method, but it is strongly
dependent on the observer’s experience and shows inter- and intra-observer
variability. A reliable and automatic method for DaTSCAN evaluation can provide
objective quantification; it is desirable for longitudinal studies, and it allows for a
better follow-up control. Moreover, it is crucial for an automated method to produce
coherent measures related to the severity of motor symptoms.
Methods: In this work, we propose a novel fully automated technique for DaTSCAN
analysis that generates quantitative measures based on striatal intensity, shape,
symmetry and extent. We tested these measures using a support vector machine
(SVM) classifier.
Results: The proposed measures reached 100 % accuracy in distinguishing between
patients with Parkinson’s disease (PD) and control subjects. We also demonstrate the
existence of a linear relationship and an exponential trend between pooled structural
and functional striatal characteristics and the Unified Parkinson’s disease Rating Scale
(UPDRS) motor score.
Conclusions: We present a novel, highly reproducible, user-independent technique
for DaTSCAN analysis producing quantitative measures directly connected to
striatum uptake and shape. In our method, no a priori assumption is required on the
spatial conformation and localization of striatum, and both uptake and symmetry
contribute to the index quantification. These measures can reliably support a
computer-assisted decision system.
Keywords: Parkinson’s disease, DaTSCAN, Computer-aided diagnosis
Background
Parkinsonian syndromes include neurological disorders characterized by common clin-
ical features such as rigidity, bradykinesia, resting tremor and postural instability [1].
The most frequent cause of parkinsonian symptoms is Parkinson’s disease (PD), a de-
generative pathology of the central nervous system due to progressive degeneration of
dopaminergic neurons in the substantia nigra, which in turn results in a loss of dopa-
mine transporters (DaT) in the striatum [2–4].
Imaging the integrity of the nigrostriatal dopaminergic pathway can improve the
accuracy of diagnosis in movement disorders and optimize the therapeutic
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approach [5, 6], especially when dealing with parkinsonian syndromes that respond
differently to medications.
Single-photon emission computed tomography (SPECT) provides a valuable tool for
dopamine neurotransmission visualization both at the pre-synaptic and post-synaptic
levels by means of several tracers [7, 8]. In particular, SPECT imaging with 123I-ioflu-
pane (123I-FP-CIT, DaTSCAN, GE Healthcare) provides an accurate in vivo marker of
the nigrostriatal dopamine terminals, and it is currently one of the most used DaT
probes [9–11]. 123I-FP-CIT is a pre-synaptic radiopharmaceutical of the DaT presenting
a significant uptake decrease in basal ganglia of PD subjects [9] and the most widely
used tracer for pre-synaptic evaluations in both Europe and the USA [12]. The utility
of this tracer for pre-synaptic evaluations has also been shown in the differential diag-
nosis between essential tremor (ET) and idiopathic parkinsonism [13–15].
Visual interpretation of DaTSCAN images according to available qualitative assess-
ment criteria [10] has traditionally been used for the diagnosis of parkinsonian symp-
toms. However, this approach is rater-dependent and prone to errors, since it relies on
gross changes in striatal DaT density. For this reason, several methods for quantitative
or semi-quantitative DaTSCAN evaluation have been proposed as a valuable tool for
obtaining reproducible diagnostic outcomes and for follow-up in longitudinal studies
[10, 16].
Semi-quantitative measures for striatal tracer uptake quantification are defined as ra-
tios between the striatal radiopharmaceutical-specific uptake and the non-specific up-
take in an area of low DaT density, usually the occipital cortex. The calculation of such
quantities requires manual positioning of regions of interest (ROIs) on the SPECT
image by a highly experienced operator, which makes the procedure time-consuming
and hampered by a considerable intra- and inter-operator variability [17, 18]. In order
to reduce analysis time, pre-defined ROIs are also used; but this approach can also be
highly arbitrary, especially in case of low striatal uptake [10, 19]. To face this issue, free
and commercial software packages [20, 21] have been developed that provide automatic
and semi-automatic placing of ROIs. The Brain Registration & Analysis Software Suite
(BRASS, Hermes Medical, SE), can automatically quantify tracer uptake in the striatum
of each hemisphere and in different subregions [22]. BRASS fits the patient data onto a
template containing a set of pre-defined ROIs and calculates the specific binding ratio
(SBR) in the whole striatum, the caudate nucleus and the putamen. A very similar ap-
proach is used in two other commercial software packages: EXINI dat (EXINI Diagnos-
tic, SE) and DaTQUANT (GE Healthcare). All these commercial products also return
information about binding in striatal subregions deriving the caudate-to-putamen up-
take ratio that can evaluate the amount of degeneration in the early stage of disease.
These methods have shown similar accuracy when compared to manual delineation
[23] but often consider only a few 2D slices for uptake quantification and do not pro-
vide measurements directly based on the shape of the uptake regions.
In the majority of these studies, the focus is on the use of DaTSCAN to separate dif-
ferent classes of patients or patients from healthy controls. Recently, authors [24] devel-
oped and evaluated Spectalizer, a fully automated method for 3D ROI extraction and
SBR evaluation. The method performed well in separating patients with PD from those
with ET but did not consider shape nor extension features of the striatum. More recent
fully automated approaches [25–27], instead, not only segmented striatal ROIs with a
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thresholding approach, but further reduced the number of voxels to include in the ana-
lysis by using a combination of statistical tests and data reduction techniques. Subse-
quently, the reduced set of voxels was fed into a supervised classifier. None of these
methods introduced shape features in the analysis pipeline.
Indeed, shape and asymmetry information about the basal ganglia can be useful not
only in PD diagnosis, where striatal damage at the onset presents unilaterally and then
spreads to the contralateral structure, but also in differential diagnosis between PD and
other parkinsonian syndromes, in which damage could be present in specific spatial
patterns.
Furthermore, only one study [20] has assessed the correlation between automatically
extracted imaging measures and symptom severity. The lack of this kind of information
represents a limitation when validating a diagnostic index, since the presence of a rela-
tionship between striatal uptake and clinical symptoms has been demonstrated by sev-
eral authors [28, 29] and is crucial for the development of an objective marker of
disease severity to help understand and monitor disease onset, severity and
progression.
For all these reasons, we propose a novel fully automated technique to analyse DaT-
SPECT images in a 3D fashion. The aim is twofold: (1) to extract relevant quantitative
measures and features based on striatal intensity, shape and symmetry and (2) to dem-
onstrate that the use of multimodal information on structural and functional integrity
of the striatum may lead to high correlation with clinical measures, thus representing a
robust marker of disease progression. To test the discriminating power of selected mea-
sures, we built a support vector machine (SVM) classifier and evaluated its accuracy in
distinguishing patients with PD from healthy subjects. We also compared the perform-
ance of our method with standard qualitative and semi-quantitative assessments.
Methods
Thirty-one patients with a diagnosis of probable PD (Group I, 18 M/13 F) and 12 age-
and sex-matched healthy controls (Group II, 5 M/7 F) underwent DaTSCAN imaging.
Demographic and clinical characteristics of the patients and controls are listed in
Table 1. Patients with PD diagnosis fulfilled the UK Parkinson’s Disease Society Brain
Bank criteria [30], and their clinical diagnoses were confirmed 2 years after the SPECT
data acquisition. An expert with years of experience in movement disorders performed
neurological examinations and clinical assessments on all patients using the Unified
Parkinson’s Disease Rating Scale Motor Examination (UPDRS-ME) [31] and the Hoehn
Table 1 Demographic and clinical features in PD and HC participants
Characteristic PD (n = 31) HC (n = 12) p value
Age (mean ± SD) 63.77 ± 9.65 62.67 ± 11 NSa
F/M 13/18 7/5 NSb
Age at onset (mean ± SD) 60.2 ± 6.4 - -
Duration of disease (mean ± SD) 7.5 ± 5.3 - -
H&Y (mean ± SD) 2.5 ± 0.5 - -
UPDRS-ME score (mean ± SD) 29.13 ± 8.65 - -
SD standard deviation, NS non-significant, UPDRS-ME Unified Parkinson’s Disease Rating Scale Motor Examination
aThis p value was determined using an unpaired t test
bThis p value was determined using χ2 test
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and Yahr (H&Y) rating scale [32] in an off phase (off medications overnight). No pa-
tient had any history of other neurological diseases other than PD. Structural magnetic
resonance imaging (MRI) excluded the presence of vascular lesions, brain tumours or
other abnormalities. The Institutional Ethics Committee of Magna Graecia University
(Catanzaro, Italy) approved the study, and all subjects gave written informed consent.
Brain imaging was performed 3 h after the administration of 200 MBq of 123I-FP-CIT
(GE-Amersham, Eindhoven, The Netherlands) using a dual-headed gamma camera
(Infinia Hawkeye, General Electric, Milwaukee, WI) equipped with a low-energy, high-
resolution collimator (SPECT). Scans were acquired with a photopeak window centred
around 159 KeV ± 10 % with a 128 × 128 image matrix (zoom factor, 1.5, 40 s per view
and 2 × 64 views). The slice thickness was 2.95 mm. Images were reconstructed using a
Butterworth filter (with a cut-off of 0.5 and an order of 6). Chang’s correction method
was used to compensate for attenuation using a coefficient, μ, of 0.11 cm−1.
Three different experts with several years of experience diagnosing movement disor-
ders according to the criteria described in [10] carried out the qualitative visual assess-
ment of the DaTSCAN images. Semi-quantitative analysis was performed selecting
three consecutive slices with the highest striatal uptakes. ROIs with fixed sizes were
manually positioned over the left and right striatum, and a third ROI in the occipital
cortex was used as reference region. Left and right striatal uptake was quantified separ-
ately. For each striatum, specific binding ratio (SBR) was calculated as follows:
SBRStr ¼ CStr−COccCOcc ; ð1Þ
where CStr and COcc are, respectively, the mean count of voxels in the striatal ROI and
the mean count of voxels in the occipital ROI. Nuclear medicine experts blinded to the
clinical data performed the procedure.
The automatic analysis of SPECT volumes consisted of five main steps. Figure 1
shows the entire process. First, we spatially registered and intensity normalized the raw
images. In the second phase, we employed a segmentation routine to extract two binary
masks corresponding to the left and right striata. Subsequently, we fitted an ellipsoid
surface on each mask using a non-linear optimization algorithm. We then used the el-
lipsoid space to extract a set of features characterizing the basal ganglia. Finally, we put
the resulting parameters into a SVM classifier. All stages are discussed in detail in the
following subsections.
Fig. 1 CADA workflow process
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Pre-processing
The pre-processing procedure involved two steps. First, we spatially normalized the
SPECT images using the FSL-FLIRT tool (Functional Magnetic Resonance Imaging
Software Library, Oxford University, UK [33, 34]) in order to ensure that the same
voxel refers to the same anatomical position across different volumes. We registered
each image to an average image of the control subjects’ group. Since our method does
not require a perfect voxel-by-voxel correspondence, but only an overall common pos-
ition of each subject, we used a six-degrees-of-freedom linear affine transform that pre-
vents deformation of the images. During this step, we obtained a template image (T) by
averaging all the co-registered images from the control group. To get a symmetric tem-
plate, we averaged T with its hemisphere mid-plane reflection. To allow for appropriate
comparison of uptake values across subjects, we performed a second pre-processing
step in which the images were intensity normalized. We employed linear intensity
normalization according to the method described in [35]. The intensity histogram in a
SPECT brain image can be fit using a positively skewed α-stable distribution. Such a
distribution is a generalized case of Gaussian distribution and can be controlled by four
parameters: α, β, γ and μ, which, respectively, describe impulsiveness, skewness, con-
centration of samples along the bulk (dispersion) and distribution shift on the x-axis
(position). By calculating the α-stable parameters for each image histogram i, it is pos-
sible to adjust all dispersions γi and location μi so that they have similar values. This is
done by calculating γ* and μ* as the mean values of the γi and μi parameters and by
using the following normalization equation:
Y ¼ aiX−bi; ð2Þ





We employed a segmentation method based upon a Gaussian mixture model (GMM)
to identify regions of high uptake on each subject [36]. The application of GMM relies
on the assumption that the intensity value at each voxel in an observed image is sam-
pled from a Gaussian mixture distribution. We assume that all voxels in the image be-
long to either a high uptake region (striatum) or a low uptake region. In the model, we
describe each voxel as a d-dimensional (d = 4) data vector x containing its intensity
value and spatial coordinates. The resulting GMM is a weighted sum of two Gaussian
densities given by the equation
p xjλð Þ ¼
XM
i¼1ωiN xjμi;Σið Þ; ð3Þ
where ωi, i = 1,…, M are the mixture weights and N(x|μi, Σi), i = 1,…, M are the Gauss-
ian component densities. Each component density is a four-variate Gaussian function
of the form,
N xjμi;Σið Þ ¼
1




x−μið Þ0Σ−1 x−μið Þ
 
; ð4Þ
with mean vector μi and covariance matrix Σi. The mixture weights satisfy the con-
straint
PM
i¼1ωi ¼ 1. The mean vectors, covariance matrices and mixture weights from
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all component densities parameterized the complete model. These parameters are col-
lectively represented by the notation
λ ¼ ωi; μi;Σif g; i ¼ 1;…;M ð5Þ
The expectation-maximization method estimates the mixture parameters [37]. In our
implementation, we assumed two Gaussian components. Once the expectation-
maximization method has converged, a complete set of parameters are returned and
used to compose two distribution functions. These functions are considered probabilis-
tic approximations of how the voxels are partitioned in the image. Thus, the function
corresponding to the highest uptake value will better describe the voxels in the stri-
atum. Formally, we carried out the segmentation by assigning each voxel to the proper
cluster according to principle of the maximum-likelihood estimation. The jth element
is labelled Lj according to the following equation
Lj ¼ max
i











 1=2 ; ð6Þ
where x is the input data and μ* and Σ* are the two estimated mixture parameters.
Since the segmentation method is completely unsupervised and not input-dependent,
the two resulting distributions will be slightly different from subject to subject in terms
of count rate, thus avoiding the need to specify a priori information or threshold values
that could be subject-specific or scanner-specific.
Ellipsoid fitting
The segmentation step produces a 3D binary mask per side of the brain; each mask de-
limits a region of high uptake and can extract quantitative measures in terms of peak
and mean uptake but is not suitable to determine spatial features such as shape, orien-
tation and position of each striatum. To evaluate striatal spatial features in a reprodu-
cible manner, we approximated the set of data points in each mask to an ellipsoid and
then derived the metrics of interest from the fit. The fitting procedure minimizes the
sum of squares of the distances between the data points and the ellipsoid surface by
solving a non-linear optimization problem.
Formally, given a set of points,
Xif gmi¼1;m > 3; X−Uð ÞTRTD R X−Uð Þ ¼ 1;
where U is the ellipsoid centre, R is an orthonormal matrix representing the ellipsoid
orientation and D is a diagonal matrix whose diagonal entries represent the reciprocal
of the squares of the half-lengths of the ellipsoid axes; the fit is obtained by minimizing





where Li is the distance from the point Xi to the ellipsoid.
Features extraction
For each subject, we calculated two measures per side: the mean ellipsoid uptake
(MEU) and a dysmorphic index (DI). We calculated the MEU by averaging the uptake
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values in a ROI defined by the fitted ellipsoid, which can be interpreted in the same
way as the SBR in the semi-quantitative approach; the larger the MEU, the higher the
uptake. We instead obtained the DI by comparing the orientation of each striatum with
the orientation of the corresponding striatum segmented from the average template
image (See Additional file 1). To do this, instead of comparing the nuclei directly, we
use the relative ellipsoids. The fitted ellipsoid is a good approximation of the striatum.
When the shape of the striatum changes as result of the diseases, it has an impact on
the ellipsoid and its orientation. The ellipsoid orientation is defined through the eigen-
vectors; thus, the problem of comparing two ellipsoids can be solved by comparing the
corresponding eigenvectors. By calculating the absolute value of the dot product be-
tween each eigenvector from the template and the corresponding eigenvector from the
subject’s striatum, we obtained a tern of values included in the interval (0, 1). Each
value in the tern is a measure of the nucleus alignment in the corresponding direction.
Finally, we calculated DI by multiplying all the values in the tern and subtracting the








   ð8Þ
where Ei
S and Ei
T are the ith ellipsoid subject eigenvector and the ith ellipsoid template
eigenvector, respectively.
When the striatum has the characteristic “comma-shape”, the ellipsoid fitted on it re-
tains a very similar orientation to the template ellipsoid. All the quantities in the tern
will be very close to one and then DI will be close to zero, indicating a non-significant
change in the striatum shape. On the contrary, when the ellipsoid is fitted on a dam-
aged nucleus, it is expected to be warped and with a different orientation with respect
to the template. So one or more values in the tern will be close to zero and DI will be
close to one, indicating a high degree of dysmorphism.
Classification
To investigate the discriminating power of the extracted measures, we built different
SVM classifiers to distinguish PD patients from control subjects and trained each clas-
sifier using a different dataset of measures. Overall, we tested four configurations:
 Experiment I: the feature vector is composed by left and right MEU values
 Experiment II: the feature vector contains left and right DI values
 Experiment III: the feature vector contains all four measures exploited in
Experiments I and II
 Experiment IV: the feature vector consists of two items corresponding to MEU and
DI of each side merged according to the following formula to obtain a shape-
modulated uptake (SMU):
SMU ¼ MEU  1−DIð Þ ð9Þ
We trained an additional model using SBR measures obtained by the semi-
quantitative approach.
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To find out whether the method is useful in decision support, we asked an expert
neurologist, blinded to the clinical data, to separate PD patients from control subjects
only based on the DaTSCAN qualitative assessment; his classification accuracy was cal-
culated and compared to the other two approaches.
We used the LIBSVM software library [38] to perform all SVM analyses.
Correlation with motor symptoms
Since it is very important, for any quantitative marker of damage, to reflect the progres-
sion of disease symptoms, we explored the relationship between our composite measure
SMU and the UPDRS-ME scores from the PD group. We performed a first-correlation
analysis without considering the symptom lateralization; we correlated the UPDRS-ME
score with the SMU value averaged over both hemispheres. In a second analysis, we split
the UPDRS-ME score in the left and right subsections; for each patient, we selected the
most affected side (UPDRS-ME-MAS) and correlated it with the contralateral SMU
measure (SMU-MAS). Moreover, we investigated the relationship of the SMU measure
with the diseases duration and the disease stage using the H&Y rating scale.
We performed all analyses by fitting linear and exponential regression models to the
data and calculating the Spearman rank correlation coefficient.
Results
We tested the proposed methodology on 43 different SPECT images. We considered
segmentation of the basal ganglia to be successful in all cases after visual inspection of
the ROIs. We performed ellipsoid fitting on the masks without errors in all subjects.
Table 2 shows the classification rates for each SVM model. Figure 2 shows the SVM
outcome from Experiment IV. We used right SMU values on the x-axis and left SMU
values on the y-axis to plot the subjects.
Table 3 shows a comparison between our method and more traditional procedures.
The proposed methodology outperformed both visual and semi-quantitative assess-
ments that, respectively, achieved accuracies of 97 % (sensitivity 96 %, specificity
100 %) and 95 % (sensitivity 100 %, specificity 83 %). The quantification values obtained
by our method showed a good correlation with the UPDRS-ME score (off medication).
SMU, averaged over both sides, showed significant negative correlation with the clinical
variable (rs = −0.55, p < 0.01). We observed a comparable relationship in the correlation
analyses between the UPDRS-ME-MAS scores and our combined measures. SMU-MAS
showed a significant negative correlation with the motor score (rs = −0.51, p < 0.005).
Figure 3 shows both the linear and exponential fits on the scatter plot of our composite
measure (SMU) versus the UPDRS motor score. The linear model (R2adj = 0.26, p < 0.01)
Table 2 Classification accuracy of the different models
Exp1 (%) Exp2 (%) Exp3 (%) Exp4 (%)
Correct rate 95.35 0.9767 100 100
AUC 96.77 0.9839 100 100
Specificity 93.55 0.9677 100 100
Sensitivity 100 100 100 100
AUC area under curve
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showed a slightly better fit than the exponential one (R2adj = 0.22, p < 0.01), but both results
had the same statistical significance.
No significant correlation was neither found between SMU and the H&Y rating scale,
nor between SMU and disease duration.
Discussion
In this work, we present a novel methodology to process DaTSCAN images. Our aim is
not only to obtain a fully automated method able to replicate all essential steps of DaTS-
CAN analysis, but also to extract a quantitative measure coherently associated with the
severity of the symptoms. The proposed method enables the extraction of reproducible
measures using the whole SPECT volume and directly connects to striatum uptake and
shape. The automated process eliminates the issue of intra- or inter-observer variability.
No other imaging data, such as MRI or computed tomography (CT), is needed to perform
the analyses. The best results are obtained by providing the classifier both extracted mea-
sures, MEU and DI, either merged in a single value or not. Both configurations are able to
split subjects without classification errors. Experiments I and II also show high accuracy;
this suggests that individual parameters are quite robust. However, best performance
exploiting all parameters together suggests the need to provide the classifier with not only
intensity/uptake data, but also shape and symmetry features.
Existing semi-quantitative measures of striatal uptake have shown good correlation
with UPDRS-ME scores [28, 29]. Moreover, this result seems quite robust, even in the
presence of confounding factors such as the assumption of PD medications. Despite
Fig. 2 SVM Classiefier results (Experiment 4): scatter plot and hiperplane
Table 3 Accuracy comparison between CADA, visual assessment and semi-quantitative assessment
Assessment method Sensitivity (%) Specificity (%) Accuracy (%)
Visuala 96 100 97
Semi-quantitativeb 100 83 95
CADA 100 100 100
aPerformed by an expert neurologist with years of experience in the field of movement disorders
bPerformed by nuclear medicine experts blinded to clinical data
Augimeri et al. EJNMMI Physics  (2016) 3:4 Page 9 of 13
the importance of such a relationship in the context of finding a robust marker of dis-
ease progression, most studies describing automated DaTSCAN analysis methods do
not address the correlation between quantitative measures and clinical scales. Two
studies, [20] and [21], are exceptions; the authors reported significant linear relation-
ships between uptake measurements (obtained with BasGan software and Neurostat
software, respectively) and the UPDRS-ME score. Our data confirm the association be-
tween DaT uptake in striata and motor symptoms, which is consistent with the hypoth-
esis that motor symptoms in PD are related to dopaminergic nigrostriatal pathology
[39]. In addition, we also found that a more accurate description of such relationship
could be described through an exponential trend, suggesting some sort of saturation ef-
fect when the striatum reaches a minimum uptake/dysmorphism value while motor
disability continues its progression. This effect could be explained in the advanced
stages of PD where the disability progression is related to the severity and extent of
extra-nigral degeneration. Moreover, while previous studies employed semi-quantitative
measures of mean uptake alone, we were able to confirm the existence of a link be-
tween motor symptom severity and a composite index, integrating structural (shape)
and functional (uptake) information. Overall, this result suggests that multimodal infor-
mation extracted from DaTSCAN images may provide further insight into the patho-
physiology of parkinsonian syndromes.
Unlike what emerged for the UPDRS-ME, neither of our correlation analyses revealed
that neither stage nor disease duration are significantly related to our striatum SPECT
measures. A possible explanation of this finding could be the sensitivity of the proposed
index to the striatum shape alteration. In fact, the index tends to show a low value,
even at the first signs of injury in the putamen, and then quickly levels off. This is con-
sistent with the usual DaT concentration reduction rate, which is faster in the early
stages of the disease than in the later stages [28] but can prevent the index from cor-
rectly following the disease progression as measured by other clinical features. More-
over, the cross-sectional design and then the spread of data caused by inter-individual
Fig. 3 Linear and exponential regression models. SMU (averaged over both hemispheres) versus
UPDRS-ME score
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differences may have reduced the effectiveness of the correlation. A longitudinal study
would better clarify this aspect.
The diagnostic process of PD is not the only scenario that would benefit from the use of
reliable, semi-quantitative measures of striatal function, shape and asymmetry, such as
those we extracted from DaTSCAN. In fact, our tool could provide a benefit in the diag-
nostic workup of parkinsonian syndromes and help ameliorate a differential diagnosis
from PD in the early stages of the disease or monitor neuroprotective treatments.
It is worth noting that the selected features (MEU and DI) are optimized to the specific
clinical setting, i.e. the diagnosis of parkinsonian syndromes. Generally, in patients with
PD, the disease progression follows a common pattern; DaT concentration starts to de-
crease in the putamen contralateral to the clinical symptoms and then progresses to the
caudate. When this happens, the striatum loses its characteristic comma-shape on DaTS-
CAN and tends to become dot-shaped or disappears altogether. In cases of low binding,
“forcing” a pre-defined ROI into a comma-shape may bias a semi-quantitative measure,
resulting in a SBR that still reaches high values, but that reflects caudate binding only,
thus not taking into account putaminal dysfunction. Instead, in our method, striatum
changes due to decreased DaT density are observed from different points of view; MEU
takes into account uptake changes, while DI detects dysmorphism in the ROI upon which
this value is calculated. For what concerns nuclei asymmetry, we did not directly provide
any asymmetry measures to any SVM model; we intrinsically introduced asymmetry in-
formation into the model since we calculated each parameter on both sides. Both MEU
and DI features can be used to derive asymmetry measures.
Although our method has proven to be reliable, we should mention a limitation. To
test the method on well-established data, we selected a PD group with a relatively ad-
vanced stage of disease; this does not allow clear evaluation of the accuracy of the pro-
posed method in the classification of earlier stages of the disease. As a future work, we
intend to select a group of de novo patients that we will follow longitudinally to test
this aspect on those with a confirmed PD diagnosis.
Conclusions
We describe a novel computer-aided diagnosis method for DaTSCAN images. Regions
of high uptake are automatically identified from three-dimensional images. The high
accuracy obtained by the SVM classifier suggests that the segmentation routine is ro-
bust and that the selected parameters well describe the striatum in terms of uptake
values, shape and symmetry. Moreover, our measures show high correlation with
UPDRS motor score. The comparison with standard qualitative and semi-quantitative
techniques suggests that a system based on this method can provide reliable support to
the diagnostic process.
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